Alex Chan

I'm Alex, Vice President in Oaktree's Life Sciences Lending fund, where I finance biotech and pharma companies. Before Oaktree, I was on the biopharma M&A team at Evercore, working on deals like AstraZeneca's $39bn acquisition of Alexion and Novo Nordisk's $1.8bn acquisition of Emisphere.

I deploy capital for LPs to help commercialize drugs that have been developed by biotech companies at a stage where raising equity is too expensive. Law degree from UCL. From Hong Kong, spent time in Canada before moving to the UK.

Ask me about life sciences lending, biopharma M&A, and financing biotech companies.